MOUNTAINTAP-30: A RANDOMIZED, PHASE 2/3 STUDY COMPARING BMS-986504 IN COMBINATION WITH NAB-PACLITAXEL AND GEMCITABINE VERSUS PLACEBO IN COMBINATION WITH NAB-PACLITAXEL AND GEMCITABINE IN PARTICIPANTS WITH UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA HARBORING HOMOZYGOUS MTAP DELETION

Registry ID

CA2400030

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

BRISTOL-MYERS SQUIBB CANADA

Start date

2025-12-05

Last update

2025-08-14

Conditions

• METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Related clinical trials

• A PHASE 2B/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
• A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER, PHASE 3 TRIAL OF QUEMLICLUSTAT AND CHEMOTHERAPY VERSUS PLACEBO AND CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAIVE METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
• A PHASE II OPEN-LABEL, MULTI-CENTER STUDY OF MEDI4736 EVALUATED AS SINGLE AGENT OR IN COMBINATION WITH TREMELIMUMAB IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

View on source registry